JDOC
Jpmorgan Healthcare Leaders ETF
Price Chart
Latest Quote
$59.22
+3.06 (+5.45%)
Current Price
| Previous Close | $56.16 |
| Open | $59.22 |
| Day High | $59.22 |
| Day Low | $59.22 |
| Volume | 82 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.90% |
| Net Assets | $8.49M |
| Expense Ratio | 0.65% |
| Category | Health |
| Fund Family | JPMorgan |
| Net Asset Value | $58.24 |
| Premium/Discount | 1.70% |
| Quarterly Dividend Yield | 0.90% |
| P/E Ratio | 29.27 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $56.96 |
| SMA50 | $56.20 |
| SMA200 | $56.20 |
| RSI | 66.59 |
| ATR | 0.5373 |
| Rel Volume | 0.19 |
Performance History
| Week | +4.61% |
| Month | +5.38% |
| Quarter | +7.28% |
| 6 Months | +2.16% |
| YTD | +2.31% |
| Year | +18.85% |
| 10 Years | +29.39% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $59.22 | 82 |
| 2026-06-24 | $58.21 | 100 |
| 2026-06-23 | $57.80 | 100 |
| 2026-06-22 | $57.17 | 100 |
| 2026-06-18 | $56.24 | 800 |
| 2026-06-17 | $56.61 | 100 |
| 2026-06-16 | $57.01 | 100 |
| 2026-06-15 | $57.18 | 100 |
| 2026-06-12 | $57.58 | 800 |
| 2026-06-11 | $57.67 | 100 |
| 2026-06-10 | $56.94 | 100 |
| 2026-06-09 | $57.50 | 200 |
| 2026-06-08 | $56.63 | 100 |
| 2026-06-05 | $56.93 | 1,100 |
| 2026-06-04 | $56.94 | 2,300 |
| 2026-06-03 | $55.25 | 500 |
| 2026-06-02 | $54.98 | 100 |
| 2026-06-01 | $55.81 | 1,700 |
| 2026-05-29 | $56.65 | 200 |
| 2026-05-28 | $56.84 | 100 |
| 2026-05-27 | $56.26 | 500 |
| 2026-05-26 | $56.20 | 100 |
About Jpmorgan Healthcare Leaders ETF
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
đ° Latest News
No news articles available at the moment. Check back later for updates on JDOC.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.